MELATONIN

Brand name:

• Slenyto®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Condition/indication:
(therapeutic use)

• Insomnia

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC submission type:

New listing (–)

Comment:

--

Submission sponsor:

Aspen Pharmacare Australia Pty Ltd

Other PBAC consideration:

• MELATONIN

Submission received for:

December 2023 PBAC meeting

Opportunity for consumer comment:

--

PBAC meeting:

Held on 06/12/2023

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

20/02/2024

Lodgement of required documentation:

06/03/2024

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 22/03/2024

Status:

Finalised

Government processes:

Commenced on 26/03/2024

Medicine listed on the PBS:

01/07/2024 (see PBS schedule)

---